What are the key changes to Board of Directors compensation?

The new Board compensation program effective immediately provides specific annual cash retainers for roles such as Board member ($130,000), committee chairs (ranging from $25,000 to $30,000), Chairman of the Board ($100,000), and independent presiding director ($50,000). Additionally, each non-management director will receive an annual equity award valued at $220,000 in restricted stock units, vesting on specific terms related to continued service or a change in control.

What was the impact of the stockholder vote on the 2020 Stock Incentive Plan?

Stockholders overwhelmingly approved the First Amendment to the 2020 Stock Incentive Plan. This amendment increases the number of shares available for issuance by 13,150,000 and extends the plan's term until April 24, 2035, providing HCA with significant equity resources for future compensation and retention.

Were there any significant changes to HCA's corporate governance structure?

Yes, stockholders approved an amendment to the company's Certificate of Incorporation to provide exculpation for officers, as permitted by Delaware law. This is intended to offer protection to officers for certain actions, aligning with common corporate governance practices.

What was the outcome of the advisory vote on executive compensation?

The company's named executive officer compensation received majority approval in a non-binding advisory vote, indicating shareholder support for the compensation practices outlined in the proxy statement.

HCA 8-K: Leadership Changes, Shareholder Matters & More

Summary

HCA Healthcare, Inc. filed an 8-K on April 28, 2025, detailing key corporate governance updates approved at their Annual Meeting on April 24, 2025. The most significant information for investors pertains to changes in Board of Directors compensation and an expansion of the company's stock incentive plan. The Board approved a new compensation program for non-management directors, which includes revised annual retainers for various committee roles and the Chairmanship, along with a significant annual equity award valued at $220,000 in restricted stock units. This reflects an alignment with attracting and retaining experienced leadership. Furthermore, HCA stockholders overwhelmingly approved an amendment to the 2020 Stock Incentive Plan, increasing the share pool by 13,150,000 shares and extending its term to 2035. This provides the company with substantial equity to incentivize future performance and employee retention. Additionally, an amendment to the Certificate of Incorporation to exculpate officers was approved, offering further protection to management. The filing also confirms the election of all nine director nominees and the ratification of Ernst & Young LLP as the independent auditor.

Key Highlights

1HCA Healthcare's Board of Directors approved a new compensation structure for non-management directors, including increased annual retainers for committee chairs and the Board Chairman, along with a $220,000 annual equity award.
2Stockholders approved an amendment to the 2020 Stock Incentive Plan, increasing the authorized shares by 13,150,000 and extending the plan's term to April 24, 2035.
3An amendment to HCA's Certificate of Incorporation was approved to provide exculpation for officers, consistent with Delaware law.
4All nine nominated directors were elected to the Board for one-year terms.
5The appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
6The company confirmed that a majority of outstanding shares voted in favor of the advisory resolution on executive compensation.
7Several stockholder proposals, including those related to golden parachutes, patient safety committee charters, and acquisition strategy reports, were not approved by shareholders.

HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 29, 2025)

Summary

Key Highlights

Frequently Asked Questions